Role of TNF-Alpha and IL10 genes in the development and clinical manifestations of psoriatic arthritis

Abstract

ObjectiveTo evaluate the impact of polymorphisms of TNF-alpha (TNFA) and IL10 genes and their association with clinical phenotypes of psoriatic arthritis (PsA). Materials and methodsThe study included 104 unrelated Venezuelan individuals, grouped into 52 patients with PsA, who fulfilled the CASPAR criteria, and 52 healthy individuals with no family history of psoriasis. The polymorphisms of the TNFA and IL10 genes were determined by Single Specific Primer-Polymerase Chain Reaction (SSP-PCR). ResultsThe GA genotype and A allele of the TNFA-238G/A polymorphism appears to confer protection against the development of PsA (OR: 0.31, 95% CI: 0.92–1.05, p=0.02). The GA genotype of the TNFA-308G/A polymorphism is associated with a late onset age of PsA (GA=60±13.17 years vs. GG=43.55±14.29 years, p=0.002), and the GG genotype of the IL10 -1082A/G polymorphism with a longer time interval between the onset of psoriasis and the development of PsA (GG=27.4±24.11 years, GA=5.47±7.23 years, AA=7.86±8.51 years, p=0.001). The CC genotypes of IL10-819 C/T and IL10-592 C/A confer risk of damage to distal interphalangeal joints (OR: 4.79, p=0.026). ConclusionsThe TNFA-238G/A polymorphism plays an important role in the development of PsA in mixed-race Venezuelans. Likewise, TNFA-308 G/A, IL10 -1082 A/G, -819C/T, -592C/A polymorphisms may modify the clinical expression of PsA.